NA
CNCE

NewEdge Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

NewEdge Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,015
Closed -$20.5K – 4331
2022
Q4 		$20.5K Buy
+4,015
New +$21.1K ﹤0.01% 2112

NewEdge Advisors's CNCE Position: Q1 2023 in Review

NewEdge Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 4,015 shares — an estimated $20.5K sold.

NewEdge Advisors first reported a position in CNCE in Q4 2022 and held it in 1 quarter. The position peaked at $20.5K in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • NewEdge Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • NewEdge Advisors sold 4,015 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $20.5K.
  • NewEdge Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
  • NewEdge Advisors's Concert Pharmaceuticals, Inc. position peaked at $20.5K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.